PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market | Page 4

4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 39
4.3.1 US 39
4.3.2 5EU 40
4.3.3 Japan 41
4.3.4 Australia 41
4.3.5 China 42
4.3.6 India 42
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of RA 50
4.4.4 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA 54
Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023
4.5 Epidemiological Forecast for RA (2013-2023) 55
4.5.1 Total Prevalent Cases of RA 55
4.5.2 Age-Specific Total Prevalent Cases of RA 57
4.5.3 Sex-Specific Total Prevalent Cases of RA 59
4.5.4 Diagnosed Prevalent Cases of RA 61
4.5.5 Age-Standardized Diagnosed Prevalence of RA 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66